Tuesday, 19 Jun 2018

You are here

Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus

Systemic lupus erythematosus (SLE) is associated with an increased risk of cardiovascular disease (CVD). The cardioprotective benefits of aspirin (ASA) are well known and the ancillary CV and diabetogenic effects of hydroxychloroquine (HCQ) have also been shown.  A current study in the Journal of Rheumatology has shown that thromboprophylaxis with low-dose ASA and HCQ) yields CVD benefits in SLE.

 

They enrolled 189 patients with SLE and monitored them for a median of 13 years and found 10  CVE occurred during followup.  They found that a higher CVE-free rate ASA-treated patients administered a cumulative dose of HCQ > 600 grams, compared with patients receiving ASA alone, or with a cHCQ dose < 600 g (p = 0.04).

Multivariate analysis showed that antimalarials plus ASA protected against thrombosis (HR 0.041 and HR 0.047, respectively), while antiphospholipid antibodies (HR 17.965) and hypertension (HR 18.054) increased the risk of a first CVE.

These data suggest that prolonged use of HCQ plus ASA has a thromboprotective in SLE.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The Microbiome and Lupus Connection Reviewed

In the current issue of the New England Journal of Medicine, Drs. James Rosenbaum and Gregg Silverstein review the pathogenesis of systemic lupus erythematosus (SLE) from the viewpoint of a dysbiolsis.

The complexity of the trillions of organisms that constitute our microbiome underscores its multiplicity of functions, including nutrient, metabolic and immune shaping functions.

SPAR Predicts ILD Progression in Systemic Sclerosis

The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding. A new analysis of two independent clinical trial cohorts shows that oxygen saturation (SpO2) < 94% after 6 minute walk time (6MWT) and the presence of arthritis predicted the development of ILD in SSc.

Low Disease Activity in Lupus Limits Damage

Patients with systemic lupus erythematosus (SLE) who were assessed as being in a low disease activity state during more than half of clinical visits had a decrease in organ damage events of approximately 50%, a retrospective study found.

Long Term Remission in SLE is Possible?

Researchers from the Toronto Lupus Clinic have described an atypical “monophasic” course in a small number (7.5%) of systemic lupus erythematosus (SLE) patients who achieved and sustained clinical remission, with most off of all medications for an average of 18 years.

Their inception SLE cohort includes patients enrolled within 18 mos of diagnosis.

Ustekinumab: A Novel Intervention in Giant Cell Arteritis

Treatment of refractory giant cell arteritis (GCA) with ustekinumab (Stelara) showed therapeutic promise as a steroid-sparing agent in a small, open-label study, Irish researchers reported.